Insider transactions

EDGAR

Denali Therapeutics Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
7 transactions, 71,134 shares
Sum of shares × price per share: 1,300,167.07

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–34 of 34

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-17 Filed 2026-11-19Schuth Alexander O. Officer: COFO and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)16,5669.60
159,033.6

Derived: shares × price per share. Exact value 159033.60.

295,561Direct (D) No
F1
  • F1 Includes 135,475 Unvested RSUs.
Open filing 0001724311-26-000016 Read from the filing’s XML Dispute this row
2026-11-17 Filed 2026-11-19Schuth Alexander O. Officer: COFO and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,566) — exercise price 9.60
Disposed (D)16,5660—40,075Direct (D) No
F3
  • F3 25% of the shares subject to the option vested on August 22, 2018 and an additional 1/48 of the shares vest monthly thereafter.
Open filing 0001724311-26-000016 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-09Chin Peter Scott Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,65422.29
36,867.66

Derived: shares × price per share. Exact value 36867.66.

204,538Direct (D) No
F1, F2, F3, F4
  • F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
  • F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • F3 Includes 142,845 Unvested RSU's
  • F4 Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.
Open filing 0002124755-26-000007 Read from the filing’s XML Dispute this row
2026-09-02 Filed 2026-09-04Thornberry Nancy Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,82422.85
247,328.4

Derived: shares × price per share. Exact value 247328.40.

20,301Direct (D) Yes
F1, F2, F3
  • F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
  • F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • F3 Includes 6,408 Unvested RSUs.
Open filing 0001797826-26-000006 Read from the filing’s XML Dispute this row
2026-09-02 Filed 2026-09-04Thornberry Nancy Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)61523.74
14,600.1

Derived: shares × price per share. Exact value 14600.10.

19,686Direct (D) Yes
F1, F4, F3
  • F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
  • F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • F3 Includes 6,408 Unvested RSUs.
Open filing 0001797826-26-000006 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Schuth Alexander O. Officer: COFO and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,76823.44
64,881.92

Derived: shares × price per share. Exact value 64881.92.

278,995Direct (D) Yes
F1, F2
  • F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
  • F2 Includes 135,475 Unvested RSUs.
Open filing 0001724311-26-000014 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Watts Ryan J. Director · Officer: President and CEO
G

Bona fide gift

Common Stock
Disposed (D)32,2200—2,120,384Indirect (I) See footnoteNo
F1, F2
  • F1 Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
  • F2 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
Open filing 0001724310-26-000007 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Schuth Alexander O. Officer: COFO and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,85725.07
71,624.99

Derived: shares × price per share. Exact value 71624.99.

281,763Direct (D) No
F1, F2, F3
  • F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
  • F2 Includes 135,475 Unvested RSUs.
  • F3 Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026.
Open filing 0001724311-26-000013 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Krognes Steve E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—38,202Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001666236-26-000015 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Krognes Steve E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F4
  • F4 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001666236-26-000015 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Schenkein David P Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—21,665Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001578200-26-000004 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Schenkein David P Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F5
  • F5 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001578200-26-000004 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—343,275Indirect (I) See FootnotesNo
F1, F2, F3, F4, F5, F6, F7, F8
  • F1 Includes 6,408 restricted stock units (each, an RSU) payable solely in common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the Adviser GP) on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the Incentive Plan). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the Board) through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
  • F2 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
  • F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
  • F8 Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.
Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—3,422,366Indirect (I) See FootnotesNo
F1, F3, F4, F5, F6, F7, F8, F9
  • F1 Includes 6,408 restricted stock units (each, an RSU) payable solely in common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the Adviser GP) on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the Incentive Plan). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the Board) through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
  • F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
  • F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
  • F8 Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.
  • F9 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Indirect (I) See FootnotesNo
F10, F2, F3, F4, F5, F6, F7
  • F10 19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date.
  • F2 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
  • F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non- Qualified Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Indirect (I) See FootnotesNo
F10, F3, F4, F5, F6, F7, F9
  • F10 19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date.
  • F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
  • F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
  • F9 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Cook Jennifer E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—32,483Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001754371-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Cook Jennifer E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F3
  • F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001754371-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Van Hauwermeiren Timothy Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—17,040Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 17,040 unvested RSUs.
Open filing 0001816206-26-000003 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Van Hauwermeiren Timothy Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F3
  • F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001816206-26-000003 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05FLATLEY JAY T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—22,628Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001189130-26-000005 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05FLATLEY JAY T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F4
  • F4 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001189130-26-000005 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Thornberry Nancy Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—31,125Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001797826-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Thornberry Nancy Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F3
  • F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001797826-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Klein Peter S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,4080—33,941Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
  • F2 Includes 6,408 unvested RSUs.
Open filing 0001478007-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Klein Peter S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66
Acquired (A)19,2260—19,226Direct (D) No
F3
  • F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Open filing 0001478007-26-000002 Read from the filing’s XML Dispute this row
2026-01-06 Filed 2026-01-08Schuth Alexander O. Officer: COFO and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)17,21816.50
284,097

Derived: shares × price per share. Exact value 284097.00.

282,828Direct (D) No
F1, F2
  • F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
  • F2 Includes 141,100 Unvested RSUs.
Open filing 0001724311-26-000005 Read from the filing’s XML Dispute this row
2026-01-06 Filed 2026-01-08Watts Ryan J. Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)35,19816.50
580,767

Derived: shares × price per share. Exact value 580767.00.

296,833Direct (D) No
F1, F2
  • F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
  • F2 Includes 184,915 Unvested RSUs.
Open filing 0001724310-26-000004 Read from the filing’s XML Dispute this row
2026-01-03 Filed 2026-01-05Watts Ryan J. Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)78,9600—332,031Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the Vesting Commencement Date) and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
  • F2 Includes 184,915 Unvested RSUs.
Open filing 0001724310-26-000001 Read from the filing’s XML Dispute this row
2026-01-03 Filed 2026-01-05Watts Ryan J. Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (236,880) — exercise price 16.27
Acquired (A)236,8800—236,880Direct (D) No
F4
  • F4 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date
Open filing 0001724310-26-000001 Read from the filing’s XML Dispute this row
2026-01-03 Filed 2026-01-05Schuth Alexander O. Officer: COFO and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)57,7000—300,046Direct (D) No
F1, F2
  • F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the Vesting Commencement Date) and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
  • F2 Includes 141,100 Unvested RSUs.
Open filing 0001724311-26-000001 Read from the filing’s XML Dispute this row
2026-01-03 Filed 2026-01-05Schuth Alexander O. Officer: COFO and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (173,100) — exercise price 16.27
Acquired (A)173,1000—173,100Direct (D) No
F4
  • F4 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
Open filing 0001724311-26-000001 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: $0.01 Prefunded Warrants — underlying Common Stock (190,523) — exercise price 0.01
Acquired (A)190,52317.49
3,332,247.27

Derived: shares × price per share. Exact value 3332247.27.

2,335,469Indirect (I) See FootnotesNo
F1, F2, F3, F4, F5
  • F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) at an exercise price of $0.01 per share with no expiration date ($0.01 Prefunded Warrants) for $17.49 per share in a public offering that closed on December 11, 2025.
  • F2 The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the Maximum Percentage). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
  • F3 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Open filing 0001193125-25-319291 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: $0.01 Prefunded Warrants — underlying Common Stock (2,095,191) — exercise price 0.01
Acquired (A)2,095,19117.49
36,644,890.59

Derived: shares × price per share. Exact value 36644890.59.

25,996,310Indirect (I) See FootnotesNo
F1, F2, F4, F5, F6
  • F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) at an exercise price of $0.01 per share with no expiration date ($0.01 Prefunded Warrants) for $17.49 per share in a public offering that closed on December 11, 2025.
  • F2 The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the Maximum Percentage). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-25-319291 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
T. Rowe Price Investment Management, Inc. COMMON STOCK12.319,634,01109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001897612-26-000739 Dispute this row
BAILLIE GIFFORD CO Common Stock7.511,960,230.0006/30/2026 Filed 2026-08-04SCHEDULE 13G/AAmendment 8Open filing 0001088875-26-000056 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK10.216,178,96306/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 1Open filing 0001897612-26-000525 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK5.48,519,19203/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001897612-26-000486 Dispute this row
FMR LLC COMMON STOCK4.26,672,999.3203/31/2026 Filed 2026-05-06SCHEDULE 13G/AAmendment 3Open filing 0000315066-26-001172 Dispute this row
Abigail P. Johnson COMMON STOCK4.26,672,999.3203/31/2026 Filed 2026-05-06SCHEDULE 13G/AAmendment 3Open filing 0000315066-26-001172 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 6Open filing 0000102909-26-001186 Dispute this row
FMR LLC COMMON STOCK5.88,536,392.3409/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-25-002719 Dispute this row
Abigail P. Johnson COMMON STOCK5.88,536,392.3409/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-25-002719 Dispute this row
Wellington Management Group LLP Common Stock3.95,664,733.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 2Open filing 0000902219-25-000288 Dispute this row
Wellington Group Holdings LLP Common Stock3.95,664,733.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 2Open filing 0000902219-25-000288 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock3.95,664,733.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 2Open filing 0000902219-25-000288 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,708,462 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015124,844
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Denali Therapeutics Inc.